Tegileridine versus sufentanil for pain relief after weight-loss surgery
Compares tegileridine with sufentanil for pain after weight-loss surgery in adults.
Plain-language title generated from the registry record
Registry title: Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing Bariatric Surgery
Key facts
- Where
- Changchun, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07844512, who can take part
Where in China
- The First Hospital of Jilin UniversityChangchun, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Hospital of Jilin University
- Trial code
- NCT07844512
- Record updated
- 3 November 2026
- Original description
This single-center, stratified randomized double-blind trial tests tegileridine, a new pain drug, for pain relief after weight-loss surgery. Researchers will compare tegileridine with standard opioid pain medicine.Read full original descriptionShow less
Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tapentadol in Patients Undergoing Bariatric Surgery
This single-center, stratified randomized double-blind trial tests tegileridine, a new pain drug, for pain relief after weight-loss surgery. Researchers will compare tegileridine with standard opioid pain medicine.
Eligible patients having bariatric surgery will be randomly assigned to one of the two treatment groups. Patients and study teams will not know which treatment each participant receives. Participants will be grouped based on whether they have obstructive sleep apnea (OSA).
The primary measurement is postoperative recovery quality in the first 24 hours after surgery using the QoR-15 survey. The study will also track pain scores, rescue pain medication use, and drug side effects for 7 days after surgery.
There is no guaranteed benefit for participants. Study pain medicines may cause side effects. Doctors will provide rescue treatment for uncontrolled pain.
Inclusion: Age 18 to 65 years old; Scheduled for elective bariatric surgery; American Society of Anesthesiologists (ASA) physical status I, II or III; Able to understand and complete the QoR-15 questionnaire; Provide written informed consent to participate in the study.
Exclusion: Participation in another interventional clinical trial within 30 days before surgery; Known allergy or hypersensitivity to opioids, tegileridine or sufentanil; History of severe respiratory disease except obstructive sleep apnea; Severe hepatic or renal dysfunction; Preoperative chronic opioid use; Pregnant or breastfeeding women; Participants who cannot complete postoperative follow-up.